Wait, we have a special
offer for you!
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Click the button below to get your discount.
Get my coupon now No thanks, I'd like to pay full price
Only Available By Prescription
Top brand choice
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
INDICATION AND USE Wynzora® (calcipotriene and betamethasone dipropionate) Cream is indicated for plaque psoriasis in adults. It is not known if Wynzora Cream is safe and effective in children.
IMPORTANT SAFETY INFORMATION Wynzora Cream is for topical use only. Patients should not use more than 100g of Wynzora Cream per week. Wynzora Cream should not be used near or in the mouth, eyes, or intravaginally. Patients should avoid using Wynzora Cream on the face, groin, or armpits, or if they have atrophy at the treatment site. Patients should apply Wynzora Cream to the affected areas of the skin once a day for up to 8 weeks. Patients should discontinue use once the plaque psoriasis is under control. Patients should not use with occlusive dressings. Hypercalcemia and hypercalciuria have been observed with use of topical calcipotriene. Wynzora Cream can cause reversible HPA axis suppression with the potential for clinical glucocorticosteroid insufficiency during and after withdrawal of treatment. Wynzora Cream may cause vision problems, including increasing the risk of cataracts and glaucoma. It is not known whether Wynzora Cream may harm your unborn baby. Breastfeeding women should not apply Wynzora Cream directly to the nipple and areola. It is not known whether topically administered calcipotriene and betamethasone dipropionate is absorbed in human milk.
